Core Viewpoint - The approval of the drug by the NMPA represents a significant advancement for the treatment of symptomatic TGCT in adult patients, indicating potential market opportunities for the company in China [1] Group 1: Company Announcement - The company, He Yu-B (02256), announced that its subsidiary, Shanghai He Yu Biomedical Technology Co., Ltd. ("He Yu Pharmaceutical"), received approval from the National Medical Products Administration (NMPA) for the drug Beijiemai (Pimicotinib Hydrochloride Capsules) [1] - The approved indication is for adult patients with symptomatic tenosynovial giant cell tumors (TGCT) that may lead to functional limitations or serious complications following surgical removal [1] - Following the approval, Merck will expedite efforts to make the product available to TGCT patients in China [1]
和誉-B：和誉医药CSF-1R抑制剂贝捷迈 获中国NMPA批准